Developer docs
API playgroundTry for free, no card

Search company profiles

Allogene Therapeutics

Full company profile

uuid0003byw

Namestring
Allogene Therapeutics
Legal namestring
Allogene Therapeutics, Inc.
Websiteurl
allogene.com
Company typeenum
Public
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic CAR T therapy, cell therapy platform, clinical stage biotechnology, gene editing technology, oncology drug development
Industry4 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Allogeneic CAR T Cell Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Revenue
TypeOne Time License
Description

Allogene is a clinical-stage company with no commercialized products. The company is developing allogeneic CAR T cell therapies for blood cancers, solid tumors, and autoimmune diseases. Revenue will be generated from product sales upon regulatory approval.

allogene.com
2Licensing and Royalties
TypeLicensing Royalties
Description

Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1AlloCAR T
Description

The company's proprietary allogeneic CAR T cell product platform

allogene.com
+3 more records
Core offering1 text field

Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies using T cells from healthy donors that are engineered with chimeric antigen receptors (CARs) and modified via gene editing to evade the patient's immune system. Its clinical pipeline includes cema-cel (anti-CD19) for first-line consolidation in MRD-positive large B-cell lymphoma, ALLO-316 (anti-CD70) for renal cell carcinoma, and ALLO-329 (dual CD19/CD70) for autoimmune diseases such as lupus, myositis, and scleroderma. All products are investigational and currently distributed only through clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 58.3% MRD clearance rate with cema-cel vs 16.7% in observation arm in ALPHA3 interim futility analysis
+3 more records
Product overview1 text field

Allogene Therapeutics is a clinical-stage biotechnology company developing the AlloCAR T platform—an investigational allogeneic CAR T cell therapy system derived from healthy donor T cells. The platform enables off-the-shelf treatment with potential to serve 100+ patients from a single manufacturing run. The core product portfolio includes: cema-cel (cemacabtagene ansegedleucel) for first-line consolidation treatment of MRD-positive large B-cell lymphoma in the pivotal ALPHA3 trial; ALLO-316 for CD70-positive solid tumors including renal cell carcinoma in the TRAVERSE trial; and ALLO-329, a next-generation dual-targeted CD19/CD70 CAR T for autoimmune diseases in the RESOLUTION trial. The platform is enhanced by proprietary technologies including Dagger® for immune evasion. Manufacturing is conducted in-house at Cell Forge 1 in Newark, California.

Product and service1 record
1Cemacabtagene ansegedleucel (cema-cel)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Servier holds exclusive license to anti-CD19 AlloCAR T investigational products from Cellectis and has granted Allogene exclusive rights to cema-cel and ALLO-501 in the U.S., all EU Member States and the United Kingdom. Servier retains rights in other territories. Favorable arbitration ruling in December 2025 reaffirmed Allogene's full development and commercial control in U.S., EU, and UK.

Strategic tierCoreTypeTechnology or Integration
Description

Allogene assumed Pfizer's strategic collaboration and licensing agreement with Cellectis, with exclusive rights to develop and commercialize allogeneic CAR T therapy programs directed at select targets. Cellectis's UCART19 technology underlies cema-cel (ALLO-501A). Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.

Strategic tierCoreTypeTechnology or Integration
Description

Allogene partnered with Foresight Diagnostics to use their investigational Foresight CLARITY™ MRD assay (powered by PhasED-Seq™) to determine enrollment eligibility for the ALPHA3 trial after first-line treatment for LBCL. The ALPHA3 trial is the first prospective trial to incorporate this investigational MRD testing for patient selection.

Strategic tierSecondaryTypeTechnology or Integration
Description

Collaboration and global gene editing licensing agreement with Arbor Biotechnologies leveraging their CRISPR gene-editing technology to support advancement of next generation allogeneic CAR T platform in autoimmune disease.

Strategic tierSecondaryTypeTechnology or Integration
Description

Collaboration and global license agreement for Antion's miRNA technology allowing tunable and simultaneous silencing of multiple targets from a single gene construct. Allogene plans to deploy Antion's multiplex miRNA with other technologies to enable next-generation strategies for immune evasion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French clinical-stage biotech and the underlying technology licensor for Allogene's cema-cel/ALLO-501 (UCART19 platform). Develops its own allogeneic CAR T candidates using TALEN gene editing, making it a direct peer and counterparty.

TypeDirect peer
Description

Clinical-stage biotech developing iPSC-derived off-the-shelf NK and T-cell therapies for cancer and autoimmune disease. Closely comparable platform strategy to Allogene's off-the-shelf cell therapy approach.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR T candidates (e.g., PBCAR19B) using ARCUS gene-editing. Direct competitor targeting similar hematology indications.

TypeEmerging player
Description

Clinical-stage cell therapy company developing engineered TCR-T therapies (Tecelra, lete-cel) for solid tumors. Comparable cell therapy modality and engineering approach, focused on solid tumor indications.

TypeDirect peer
Description

Clinical-stage allogeneic CAR T developer (CB-010, CB-011) using CRISPR-based gene editing for hematologic malignancies. Direct competitor to Allogene in the off-the-shelf CAR T space.

TypeDirect peer
Description

Allogeneic T-cell therapy developer (tab-cel/EBVALLO) using a similar off-the-shelf model for oncology indications. Direct peer in the allogeneic cell therapy category.

TypeDirect peer
Description

Clinical-stage gene-editing biotech developing allogeneic CAR T therapies (e.g., CTX112) for hematologic malignancies and autoimmune disease. Direct competitor in off-the-shelf CAR T with overlapping gene-editing approach.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Major oncology incumbent with approved autologous CAR T therapies (Breyanzi, Abecma) and bispecific antibodies in LBCL. Competes in the same patient populations Allogene is targeting with cema-cel.

TypeBroad incumbent
Description

Owner of Yescarta (autologous CAR T) and Allogene founders' prior employer. Dominant incumbent in the CAR T market; Allogene's allogeneic platform is positioned as the off-the-shelf alternative to Gilead's autologous franchise.

TypeBroad incumbent
Description

Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi for solid tumors. Adjacent cell therapy modality competing for similar oncology infrastructure and patient populations.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allogene Therapeutics

Allogeneic CAR T Cell Therapyallogene.com

Allogene Therapeutics firmographics

Firmographics
Name
Allogene Therapeutics
Legal name
Allogene Therapeutics, Inc.
Website
https://allogene.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Allogene Therapeutics industry classification

Industry
Product category
Allogeneic CAR T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Allogeneic CAR T therapy
  • Cell therapy platform
  • Clinical stage biotechnology
  • Gene editing technology
  • Oncology drug development

Where Allogene Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Allogene Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Product Revenue: Allogene is a clinical-stage company with no commercialized products. The company is developing allogeneic CAR T cell therapies for blood cancers, solid tumors, and autoimmune diseases. Revenue will be generated from product sales upon regulatory approval.
  2. Licensing and Royalties: Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Allogene Therapeutics product offering

Product offering

Core offering

Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies using T cells from healthy donors that are engineered with chimeric antigen receptors (CARs) and modified via gene editing to evade the patient's immune system. Its clinical pipeline includes cema-cel (anti-CD19) for first-line consolidation in MRD-positive large B-cell lymphoma, ALLO-316 (anti-CD70) for renal cell carcinoma, and ALLO-329 (dual CD19/CD70) for autoimmune diseases such as lupus, myositis, and scleroderma. All products are investigational and currently distributed only through clinical trials.

Product overview

Allogene Therapeutics is a clinical-stage biotechnology company developing the AlloCAR T platform—an investigational allogeneic CAR T cell therapy system derived from healthy donor T cells. The platform enables off-the-shelf treatment with potential to serve 100+ patients from a single manufacturing run. The core product portfolio includes: cema-cel (cemacabtagene ansegedleucel) for first-line consolidation treatment of MRD-positive large B-cell lymphoma in the pivotal ALPHA3 trial; ALLO-316 for CD70-positive solid tumors including renal cell carcinoma in the TRAVERSE trial; and ALLO-329, a next-generation dual-targeted CD19/CD70 CAR T for autoimmune diseases in the RESOLUTION trial. The platform is enhanced by proprietary technologies including Dagger® for immune evasion. Manufacturing is conducted in-house at Cell Forge 1 in Newark, California.

Differentiator

Problem solved

Functional benefit

Brands

  • AlloCAR T: The company's proprietary allogeneic CAR T cell product platform
  • Dagger
  • Cell Forge 1
  • TurboCAR

Products and services

  • Cemacabtagene ansegedleucel (cema-cel)

Quantifiable outcome

  • 58.3% MRD clearance rate with cema-cel vs 16.7% in observation arm in ALPHA3 interim futility analysis
  • +3 more outcomes

Companies that use Allogene Therapeutics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Allogene Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Allogene Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and secondary.

  • ServiercoreTechnology or Integration · 1 December 2025Servier holds exclusive license to anti-CD19 AlloCAR T investigational products from Cellectis and has granted Allogene exclusive rights to cema-cel and ALLO-501 in the U.S., all EU Member States and the United Kingdom. Servier retains rights in other territories. Favorable arbitration ruling in December 2025 reaffirmed Allogene's full development and commercial control in U.S., EU, and UK.
  • CellectiscoreTechnology or IntegrationAllogene assumed Pfizer's strategic collaboration and licensing agreement with Cellectis, with exclusive rights to develop and commercialize allogeneic CAR T therapy programs directed at select targets. Cellectis's UCART19 technology underlies cema-cel (ALLO-501A). Cellectis is eligible to receive up to $340 million in development and sales milestone payments plus low double-digit royalties on net sales of cema-cel under the Servier Agreement.
  • Foresight DiagnosticscoreTechnology or IntegrationAllogene partnered with Foresight Diagnostics to use their investigational Foresight CLARITY™ MRD assay (powered by PhasED-Seq™) to determine enrollment eligibility for the ALPHA3 trial after first-line treatment for LBCL. The ALPHA3 trial is the first prospective trial to incorporate this investigational MRD testing for patient selection.
  • Arbor BiotechnologiessecondaryTechnology or IntegrationCollaboration and global gene editing licensing agreement with Arbor Biotechnologies leveraging their CRISPR gene-editing technology to support advancement of next generation allogeneic CAR T platform in autoimmune disease.
  • AntionsecondaryTechnology or IntegrationCollaboration and global license agreement for Antion's miRNA technology allowing tunable and simultaneous silencing of multiple targets from a single gene construct. Allogene plans to deploy Antion's multiplex miRNA with other technologies to enable next-generation strategies for immune evasion.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Allogene Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cellectis: French clinical-stage biotech and the underlying technology licensor for Allogene's cema-cel/ALLO-501 (UCART19 platform). Develops its own allogeneic CAR T candidates using TALEN gene editing, making it a direct peer and counterparty.
  • Fate Therapeutics: Clinical-stage biotech developing iPSC-derived off-the-shelf NK and T-cell therapies for cancer and autoimmune disease. Closely comparable platform strategy to Allogene's off-the-shelf cell therapy approach.
  • Precision Biosciences: Clinical-stage cell therapy company developing allogeneic CAR T candidates (e.g., PBCAR19B) using ARCUS gene-editing. Direct competitor targeting similar hematology indications.
  • Caribou Biosciences: Clinical-stage allogeneic CAR T developer (CB-010, CB-011) using CRISPR-based gene editing for hematologic malignancies. Direct competitor to Allogene in the off-the-shelf CAR T space.
  • Atara Biotherapeutics: Allogeneic T-cell therapy developer (tab-cel/EBVALLO) using a similar off-the-shelf model for oncology indications. Direct peer in the allogeneic cell therapy category.
  • CRISPR Therapeutics: Clinical-stage gene-editing biotech developing allogeneic CAR T therapies (e.g., CTX112) for hematologic malignancies and autoimmune disease. Direct competitor in off-the-shelf CAR T with overlapping gene-editing approach.

Emerging players

  • Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T therapies (Tecelra, lete-cel) for solid tumors. Comparable cell therapy modality and engineering approach, focused on solid tumor indications.

Broad incumbents

  • Bristol Myers Squibb: Major oncology incumbent with approved autologous CAR T therapies (Breyanzi, Abecma) and bispecific antibodies in LBCL. Competes in the same patient populations Allogene is targeting with cema-cel.
  • Gilead Sciences (Kite Pharma): Owner of Yescarta (autologous CAR T) and Allogene founders' prior employer. Dominant incumbent in the CAR T market; Allogene's allogeneic platform is positioned as the off-the-shelf alternative to Gilead's autologous franchise.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi for solid tumors. Adjacent cell therapy modality competing for similar oncology infrastructure and patient populations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Allogene Therapeutics social profiles

Digital presence

Allogene Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allogene Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Allogene Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allogene Therapeutics M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allogene Therapeutics

What does Allogene Therapeutics do?

Allogene Therapeutics develops allogeneic (off-the-shelf) CAR T cell therapies using T cells from healthy donors that are engineered with chimeric antigen receptors (CARs) and modified via gene editing to evade the patient's immune system. Its clinical pipeline includes cema-cel (anti-CD19) for first-line consolidation in MRD-positive large B-cell lymphoma, ALLO-316 (anti-CD70) for renal cell carcinoma, and ALLO-329 (dual CD19/CD70) for autoimmune diseases such as lupus, myositis, and scleroderma. All products are investigational and currently distributed only through clinical trials.

Is Allogene Therapeutics a public or private company?

Allogene Therapeutics is a public company. It is classified as public and is currently operating.

When was Allogene Therapeutics founded?

Allogene Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Allogene Therapeutics based?

Allogene Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Allogene Therapeutics make money?

Two revenue lines are on record. Product Revenue is the primary driver. The others are licensing and Royalties.

Who are Allogene Therapeutics's main competitors?

Direct peers on record are Cellectis, Fate Therapeutics, Precision Biosciences, Caribou Biosciences, Atara Biotherapeutics and CRISPR Therapeutics. Adaptimmune is listed as an emerging player. Broad incumbents are Bristol Myers Squibb, Gilead Sciences (Kite Pharma) and Iovance Biotherapeutics.

Does Allogene Therapeutics have an API?

No public API is recorded for Allogene Therapeutics.

What industry is Allogene Therapeutics in?

Allogene Therapeutics's product category is Allogeneic CAR T Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewALLO: ALPHA3 showed 58% MRD clearance vs 16%; EFS analyses are expected in 2027 and 2028ALPHA3's April 2026 interim showed 58% MRD clearance with cema-cel versus 16% with observation, and a clean outpatient safety profile. An EFS interim is assumed for mid-2027, with the primary analysis expected in 2028.Seeking AlphaAllogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 TranscriptAllogene Therapeutics CEO Zachary Roberts presented at the UBS Global Biopharma Conference, highlighting Phase III data for ALLO-329 in diffuse cutaneous scleroderma showing symptom improvements without lymphodepletion. He also noted progress in autoimmune disease research.American Banking and Market NewsAllogene Therapeutics, Inc. $ALLO Stock: Candriam S.C.A. Increases StakeCandriam S.C.A. increased its stake in Allogene Therapeutics by 25.1% in Q3, buying 1,086,524 shares to hold 5,422,820 shares. Other institutions like BlackRock and Frazier also added positions, while insiders sold shares. Analysts rate the stock a Moderate Buy with a $8.30 price target.Seeking AlphaAllogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases TranscriptAllogene Therapeutics held a conference call to present preliminary safety and efficacy data from the Phase I RESOLUTION trial of ALLO-329 in autoimmune diseases. The company also announced a poster presentation at ACR Convergence, with data available on its website.Business & FinancialAllogene Therapeutics Reports First Clinical Data From Phase 1 RESOLUTION Study Of ALLO-329 In Autoimmune DiseaseAllogene Therapeutics reported first clinical data from its Phase 1 RESOLUTION study of ALLO-329 in autoimmune disease, showing early and durable improvements in skin scores among 10 scleroderma patients. Eight of 10 achieved a five-point or greater reduction in modified Rodnan skin score, with four achieving total scores below 10. The company plans a Phase 2 regimen selection and a 2027 data readout.American Banking and Market NewsAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Allogene Therapeutics from hold to sell. The stock has a consensus rating of Moderate Buy with an average price target of $8.30. CFO Geoffrey Parker sold 36,342 shares, and institutional investors own 83.63% of the company.TradingViewAllogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q SummaryAllogene Therapeutics reported no collaboration revenue in Q3 2026, unchanged from a year earlier, while its net loss widened to $50.37 million. Diluted EPS was -$0.15, and cash, cash equivalents, and investments totaled $388.9 million at September 30, 2026, with funding expected in Q1 2029.Seeking AlphaAllogene Therapeutics GAAP EPS of -$0.15 in-line (ALLO:NASDAQ)Allogene Therapeutics reported Q3 GAAP EPS of -$0.15, in-line with expectations. Research and development expenses were $41.9 million, including $2.9 million of non-cash stock-based compensation. The company's stock fell 8.4% to $1.09.MarketBeatAllogene Therapeutics (ALLO) Expected to Release Earnings on ThursdayAllogene Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5th, after market close. Analysts estimate EPS of -$0.1466 and revenue of $0.00 million, with the stock opening at $1.30. The company's average analyst rating is Moderate Buy with a target price of $8.30.Stock TitanAllogene Therapeutics to Join 3 Investor ConferencesAllogene Therapeutics announced it will participate in three investor conferences in November and December 2026 in London and New York. The company, a clinical-stage biotech developing allogeneic CAR T products, will present at UBS, Jefferies, and Piper Sandler conferences. Webcasts will be posted to its website.